

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
27 December 2018 (27.12.2018)



(10) International Publication Number
WO 2018/237097 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2018/038638

(22) International Filing Date:
20 June 2018 (20.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/522,559 20 June 2017 (20.06.2017) US

(71) Applicant: **AMGEN INC.** [US/US]; ONE AMGEN CENTER DRIVE, THOUSAND OAKS, California 91320-1799 (US).

(72) Inventors: **BATES, Darren L.**; 238 Saint Croix Court, Oak Park, California 91377 (US). **SHI, Donghui**; 3198 Rickey Court, Thousand Oaks, California 91362 (US). **LLOYD, David J.**; 458 Via Gregorio, Thousand Oaks, California 91320 (US). **BONDARENKO, Pavel**; 1774 Blossom Court, Thousand Oaks, California 91320 (US). **MICHAELS, Mark L.**; 5007 Texhoma Avenue, Encino, California 91316 (US). **HAGER, Todd**; 28726 Aries Street, Agoura Hills, California 91301 (US). **MIN, Xiaoshan**; 2108 Clarice Lane, Burlingame, California 94010 (US). **UMEDA, Aiko**; 21400 Burbank Blvd., Apt. 318, Woodland Hills, California 91367 (US). **CHEN, Irwin**; 1875 Kelton Avenue, #202, Los Angeles, California 90025 (US). **WANG, Zhulun**; 660 Glenbrook, Palo Alto, California 94306 (US).

(74) Agent: **DERMOTT, Jonathan M.**; AMGEN INC., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS

(57) Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.



WO 2018/237097 A1